Bio & Experience

• Moderated US, Canada, UK & EU5 oncology interviews related to genomic / MCED / MRD / PSMA PET testing, biomarker-driven therapies (e.g., EGFR, MET, gBRCA), and advanced modalities (checkpoint inhibitors, CAR-T, ADCs, bispecific antibodies) across NSCLC, Breast, Prostate, CRC, mPanC, Melanoma, NMIBC, mRCC, Endometrial, and Hematologic malignancies (MM, DLBCL, FL, CLL)

• Moderated and consulted across rare disease, immunology, cardiology, and metabolic/renal markets, including ATTR (-CM, -PN, -Mixed), CIDP, IgAN, SMA, RA, UC/CD, CRSsNP, Lupus, SPAF, VTE, nHCM, Factor XI inhibitors, and MASH/MASLD

• Expertise in moderating interviews with diverse stakeholder groups, including HCPs, KOLs, patients, caregivers, and payers/pharmacists across modalities

• Proficient in end-to-end qualitative execution (screener design, discussion guides, 1-on-1 IDIs, focus groups, and strategic readouts) to inform patient journey, buying process, TPP/SIMALTO assessment, emotional understanding, profiling/segmentation, qual-e-quant, and brand positioning

• Prior strategic consulting roles across Charles River Associates (CRA), Trinity Life Sciences (Engagement Manager, through 2023), and C1 Consulting

• Track record of scale: 1,000+ 1-on-1 qualitative interviews conducted, 400+ oncologists & KOLs interviewed, and 50+ strategic qualitative projects managed

• Operating as an independent S-Corp (Healthy Dialogue Moderation, LLC) — W-9 ready with seamless client onboarding and contracting (Based in Austin, TX; US, Canada, UK & EU5 market coverage)

Education

• MS in Biotechnology (Northwestern University)

• BSc in Evolutionary Biology (University of Toronto)

• Additional graduate coursework in Transposable Elements & Genomics (University of Toronto)